NM
LENZ

Newtyn Management’s LENZ Therapeutics LENZ Stock Holding History

Newtyn Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-77,520
Closed -$1.35M – 53
2023
Q3 		$1.35M Buy
+77,520
New +$1.35M 0.33% 36

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Newtyn Management's LENZ Position: Q4 2023 in Review

Newtyn Management sold out of LENZ Therapeutics (LENZ) in Q4 2023, closing a stake of 77,520 shares — an estimated $1.35M sold.

Newtyn Management first reported a position in LENZ in Q3 2023 and held it in 1 quarter. The position peaked at $1.35M in Q3 2023. 63 funds tracked by Wall St. Rank hold LENZ as of Q4 2023.

  • Newtyn Management reported no remaining LENZ Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Newtyn Management sold 77,520 LENZ Therapeutics shares in Q4 2023, an estimated $1.35M.
  • Newtyn Management first reported a position in LENZ Therapeutics in Q3 2023 and held it in 1 quarter.
  • Newtyn Management's LENZ Therapeutics position peaked at $1.35M in Q3 2023.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2023.

Based on Newtyn Management's 13F filing for Q4 2023, filed 14 Feb 2024.